TriSalus (TLSI) CEO Mary Szela adds 39,682 shares in open-market stock purchase

Rhea-AI Filing Summary

TriSalus Life Sciences CEO Mary T. Szela bought 39,682 shares of common stock in an open-market purchase at a weighted average price of $2.59 per share. After this transaction, she directly holds 1,065,215 common shares.

A footnote explains these purchases are matchable under Section 16(b) against earlier sales that were made solely to cover tax withholding on vesting restricted stock units. The filing states she paid $27,573.70 to the company, equal to the profit from this short-swing transaction.

Insights

Equity compensation and insider trading analyst

CEO made an open-market share purchase, with profit from a related short-swing trade repaid to the company.

The filing shows CEO Mary T. Szela purchased 39,682 shares of TriSalus Life Sciences common stock at a weighted average of $2.59 per share. Following this buy, her direct holdings total 1,065,215 shares, indicating a modest increase in her equity stake.

A key detail is the Section 16(b) disclosure. The purchase is matchable against prior sales that occurred at $4.13 and $3.85 per share to cover tax withholding on vested restricted stock units, which the filing notes were not discretionary sales. The CEO remitted $27,573.70 to the issuer, equal to the profit realized on the short-swing transaction as required under these rules.

The transaction is characterized as an open-market purchase rather than compensation-related issuance, and there are no remaining derivative (option) positions listed in this filing. Future company disclosures may further clarify how insider ownership levels evolve over subsequent reporting periods.

Insider Trade Summary

Net Buyer: 39,682 shares ($102,776)

Net Buy 1 txn

Insider Szela Mary T

Role CEO and President

Bought 39,682 shs ($103K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	39,682	$2.59	$103K

Holdings After Transaction: Common Stock — 1,065,215 shares (Direct, null)

Footnotes (1)

1. The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 39,682 shares at a weighted average price of $2.59, with the Reporting Person's sales of 4,358 shares of common stock at a price per share of $4.13 on March 11, 2026 and of 15,944 shares of common stock at a price per share of $3.85. The prior sales represented shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person, and did not represent discretionary sales by the Reporting Person. The Reporting Person paid $27,573.70 to the Issuer, representing the full amount of profit realized in connection with the short-swing transaction. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.48 to $2.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Key Figures

Shares purchased: 39,682 shares Purchase price: $2.59 per share Holdings after transaction: 1,065,215 shares +4 more

7 metrics

Shares purchased 39,682 shares Open-market purchase of common stock

Purchase price $2.59 per share Weighted average price for the 39,682-share buy

Holdings after transaction 1,065,215 shares CEO’s direct common stock ownership following purchase

Short-swing profit repaid $27,573.70 Amount paid by CEO to issuer under Section 16(b)

Prior tax-related sale 1 4,358 shares at $4.13 Sale to cover tax withholding on RSU vesting

Prior tax-related sale 2 15,944 shares at $3.85 Additional sale to cover tax withholding on RSU vesting

Purchase price range $2.48–$2.62 per share Range of individual trade prices within the reported buy

Key Terms

Section 16(b), short-swing transaction, restricted stock units, weighted average price, +1 more

5 terms

Section 16(b) regulatory

"The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934"

A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.

short-swing transaction regulatory

"profit realized in connection with the short-swing transaction"

restricted stock units financial

"in connection with the vesting of restricted stock units previously granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Szela Mary T

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER COLORADO 80031

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		P(1)		39,682	A	$2.59(2)	1,065,215	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 39,682 shares at a weighted average price of $2.59, with the Reporting Person's sales of 4,358 shares of common stock at a price per share of $4.13 on March 11, 2026 and of 15,944 shares of common stock at a price per share of $3.85. The prior sales represented shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person, and did not represent discretionary sales by the Reporting Person. The Reporting Person paid $27,573.70 to the Issuer, representing the full amount of profit realized in connection with the short-swing transaction.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.48 to $2.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

	/s/ Mary Szela	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did TriSalus Life Sciences (TLSI) CEO Mary T. Szela buy in this Form 4 filing?

Mary T. Szela bought 39,682 shares of TriSalus Life Sciences common stock. The shares were acquired in an open-market transaction at a weighted average price of $2.59 per share, modestly increasing her direct ownership position in the company.

What is Mary T. Szela’s total TriSalus Life Sciences (TLSI) shareholding after the reported transaction?

After the transaction, Mary T. Szela directly holds 1,065,215 TriSalus Life Sciences common shares. This total reflects her position following the purchase of 39,682 shares reported in the filing at a weighted average price of $2.59 per share.

How does Section 16(b) affect the TriSalus Life Sciences (TLSI) CEO’s recent stock trades?

The filing states the CEO’s 39,682-share purchase is matchable under Section 16(b) with prior sales. Those earlier sales covered tax withholding on restricted stock vesting. She paid $27,573.70 to TriSalus, equaling the profit from the short-swing transaction, as required.

Were the prior TriSalus Life Sciences (TLSI) stock sales by the CEO discretionary?

The filing explains the earlier sales matched to this purchase were not discretionary. They involved 4,358 and 15,944 shares sold at $4.13 and $3.85 solely to satisfy tax withholding on vesting restricted stock units previously granted to the CEO.

What price range did the TriSalus Life Sciences (TLSI) CEO pay for the purchased shares?

The Form 4 reports a weighted average purchase price of $2.59 per share. It notes the CEO bought the shares in multiple transactions, with individual prices ranging from $2.48 to $2.62, and offers to provide full detail on each trade upon request.